turoctocog alfa

Turoctocog alfa is a recombinant, B-domain truncated human coagulation factor VIII used for the treatment and prophylaxis of bleeding in patients with hemophilia A (congenital factor VIII deficiency). It is produced using Chinese hamster ovary (CHO) cells and does not contain any human or animal proteins. The drug functions by replacing deficient or defective endogenous factor VIII in hemophilia A patients, thereby restoring the intrinsic pathway of blood coagulation. Upon activation by thrombin, the truncated B-domain is cleaved off, resulting in an active FVIII molecule that closely resembles endogenous FVIIIa. Turoctocog alfa binds to von Willebrand Factor (vWF) in circulation; once activated, it acts as a cofactor for activated factor IX to accelerate conversion of factor X to Xa—ultimately leading to thrombin generation and fibrin clot formation. Clinical trials have demonstrated its efficacy for both on-demand treatment and prophylaxis of bleeding episodes as well as perioperative management[1][4][5][8].

Brand names

NovoEight

Other names

recombinant factor VIIIrFVIIIB-domain truncated recombinant factor VIII